Innovation Pharmaceuticals Inc (IPIX)

[Patientspeople]

Facts and Evidence Based Medicine - Earlier Trial below that shows Great Efficacy and Safety of Prurisol in Psoriasis. Easily Found Public Data

• The primary efficacy endpoint of percentage of subjects with ≥ 2-point improvement in IGA was met with the 200 mg Prurisol dose group achieving highest magnitude of effect
• A clear progressive decrease of IGA scores to lower values was seen as early as 2 weeks and further improved out through 12 weeks (200 mg group)
[Note: The p-values from this study were generated for informational purposes only and statistical significance was not a criterion for study success]
• Sufficient clinical improvement was observed to warrant more detailed examination of clinical responses to treatment at 200 mg and higher dosing levels
• Prurisol was generally well tolerated
• As 2/3rd of these subjects (200 mg group) had Baseline IGA=3 (“moderate” psoriasis), their favorable
responses serve as a bridge to investigate Prurisol in a moderate-to-severe psoriasis population
• A Phase 2b trial is planned to begin 2H 2016 evaluating higher dosing regimens (300mg and 400mg) in moderate-to-severe psoriasis, using proportion of subjects achieving PASI75 at Week 12 as the primary endpoint